Invention Grant
- Patent Title: VEGF antagonist formulations for intravitreal administration
- Patent Title (中): 用于玻璃体内给药的VEGF拮抗剂制剂
-
Application No.: US13329770Application Date: 2011-12-19
-
Publication No.: US08481046B2Publication Date: 2013-07-09
- Inventor: Eric Furfine , Daniel Dix , Kenneth Graham , Kelly Frye
- Applicant: Eric Furfine , Daniel Dix , Kenneth Graham , Kelly Frye
- Applicant Address: US NY Tarrytown
- Assignee: Regeneron Pharmaceuticals, Inc.
- Current Assignee: Regeneron Pharmaceuticals, Inc.
- Current Assignee Address: US NY Tarrytown
- Agent Joseph E. Zahner; Valeta Gregg
- Main IPC: A61K38/18
- IPC: A61K38/18 ; C07K14/71
Abstract:
Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence of residues 27-457 of SEQ ID NO:4.
Public/Granted literature
- US20120087929A1 VEGF Antagonist Formulations for Intravitreal Administration Public/Granted day:2012-04-12
Information query
IPC分类:
